Cancer is the leading cause of disease burden in Australia — with approximately 160,000 new cancer cases diagnosed annually. Research into cancer causes, prevention, detection, treatment, and survivorship is funded through a combination of government, charitable, and industry sources. Understanding this landscape matters for cancer researchers, oncology professionals, cancer-specific organisations, and the philanthropic sector investing in finding better answers to cancer.
Cancer incidence and mortality
Cancer disparities
Cancer outcomes are not equal:
- Aboriginal and Torres Strait Islander Australians have higher cancer mortality rates
- Rural and regional Australians face later-stage diagnosis and lower survival
- Socioeconomic disadvantage affects cancer risk (smoking, obesity) and outcomes (access to treatment)
National Health and Medical Research Council (NHMRC)
The NHMRC is Australia's primary health research funder — cancer research receives the largest share of NHMRC health research investment:
- Project grants (competitive research funding for specific projects)
- Investigator grants (career development funding for researchers)
- Centre of Research Excellence grants (collaborative research centres)
- Clinical trial grants
NHMRC funding is highly competitive — application success rates typically 10-20%.
Medical Research Future Fund (MRFF)
The MRFF provides additional research funding beyond NHMRC:
- Mission-based investment in specific disease areas
- Clinical trial funding
- Translation research (moving lab discoveries to clinical practice)
- Rapid research response to emerging health challenges
Cancer has been a major beneficiary of MRFF investment.
Australian Institute of Health and Welfare (AIHW)
AIHW funds cancer surveillance and data — providing the evidence base for research and policy.
State government cancer research
States fund cancer research through:
- State medical research funding bodies (HMRI in NSW, MHTP in Victoria)
- State cancer councils (some fund research directly)
- University research infrastructure
Cancer Council funding model
Cancer Council Australia is the national body — umbrella organisation for state Cancer Councils that are each independently governed:
- Cancer Council NSW, Victoria, Queensland, WA, SA, Tasmania, ACT, NT
Research funding
Cancer Councils collectively fund hundreds of millions in cancer research:
- Project grants for laboratory and clinical research
- Fellowship and scholarship programmes
- Consumer-driven research (funding research priorities identified by cancer patients and carers)
- Prevention and early detection research
Cancer fundraising
Cancer Councils raise significant funds from the public:
- Relay for Life
- Daffodil Day
- Australia's Biggest Morning Tea
- Pink Ribbon (in partnership with other breast cancer organisations)
Beyond the Cancer Councils, disease-specific organisations fund cancer research and support:
Breast Cancer
- Breast Cancer Network Australia (BCNA) — advocacy, support, some research
- National Breast Cancer Foundation — dedicated breast cancer research funding
- Pink Ribbon initiatives — public fundraising for breast cancer
Prostate Cancer
- Prostate Cancer Foundation of Australia — research, support, awareness
Lung Cancer
- Lung Foundation Australia — advocacy and research for Australia's deadliest cancer
Leukaemia / Blood Cancer
- Leukaemia Foundation — research funding and patient support
Brain Cancer
- Mark Hughes Foundation — brain cancer research
- Cure Brain Cancer Foundation — dedicated brain cancer research
Bowel Cancer
- Bowel Cancer Australia — advocacy and research
Children's Cancer
- Children's Cancer Institute — dedicated childhood cancer research
- Camp Quality and similar organisations — quality of life for children with cancer
Melanoma
- Melanoma Institute Australia — melanoma research and clinical trials
Rare Cancers
- Rare Cancers Australia — advocacy and support for patients with rare cancers
Clinical trials are the bridge between laboratory discovery and clinical practice:
- Industry-sponsored trials (pharmaceutical company funded)
- Investigator-initiated trials (researcher-designed, requiring external funding)
- Cooperative trials groups (Cancer Trials Australia, Australia New Zealand Breast Cancer Trials Group)
Funding for investigator-initiated trials comes from NHMRC, MRFF, Cancer Councils, and disease-specific foundations. Accessing trial funding requires evidence of preclinical data, trial design expertise, and institutional support.
Cancer research in Australia increasingly involves cancer patients and survivors as active research partners — not just research subjects:
- Consumer representatives on grant panels (Cancer Australia, NHMRC)
- Consumer co-researchers in project teams
- Patient-defined research priorities
- Lay summaries required in grant applications
This shift reflects recognition that consumer involvement improves research relevance and quality.
Significance and innovation
NHMRC and other peer-reviewed funders assess whether research addresses an important gap and whether the approach is innovative. Significance alone (cancer is important) is not sufficient — show the specific gap your research addresses.
Track record
Cancer research funding is competitive — a strong publication record and prior funding success matter. Early career researchers should apply for career development grants before competing for project grants.
Translation potential
Funders increasingly ask about translation — how will this research benefit cancer patients? Even basic science grants benefit from articulating eventual clinical relevance.
Collaboration
Multi-disciplinary, multi-institutional cancer research teams are more fundable than solo investigator grants. International collaborations add credibility.
Consumer involvement
Demonstrate genuine consumer involvement in research design — not token inclusion. Cancer Councils and consumer advocacy groups can provide consumer advisors.
Tahua's grants management platform supports cancer research organisations and health funders — with grant portfolio management, research milestone tracking, clinical trial reporting, and the tools that help cancer research institutions manage complex multi-funder research portfolios.